Download MendeleyDiscovery of a Series of Indole-2 Carboxamides as Selective Secreted Phospholipase A2Type X (sPLA2-X) Inhibitors.
Knerr, L., Giordanetto, F., Nordberg, P., Pettersen, D., Selmi, N., Beisel, H.G., de la Motte, H., Olsson, T., Perkins, T.D.J., Herslof, M., Mansson, A., Dahlstrom, M., Starke, I., Broddefalk, J., Saarinen, G., Klingegard, F., Hurt-Camejo, E., Rosengren, B., Brengdahl, J., Jansen, F., Rohman, M., Sandmark, J., Hallberg, K., Akerud, T., Roth, R.G., Ahlqvist, M.(2018) ACS Med Chem Lett 9: 594-599
- PubMed: 30034585
- DOI: https://doi.org/10.1021/acsmedchemlett.7b00505
- Primary Citation of Related Structures:
5OW8, 5OWC - PubMed Abstract:
In order to assess the potential of sPLA 2 -X as a therapeutic target for atherosclerosis, novel sPLA 2 inhibitors with improved type X selectivity are required. To achieve the objective of identifying such compounds, we embarked on a lead generation effort that resulted in the identification of a novel series of indole-2-carboxamides as selective sPLA2-X inhibitors with excellent potential for further optimization.
Organizational Affiliation:
Medicinal Chemistry, Translational Sciences, Bioscience and Drug Metabolism and Pharmacokinetics, Cardiovascular and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg SE-431 89, Sweden.
